Guggenheim Reiterates Buy on Johnson & Johnson, Maintains $270 Price Target

Benzinga · 1d ago
Guggenheim analyst Vamil Divan reiterates Johnson & Johnson (NYSE:JNJ) with a Buy and maintains $270 price target.